Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
AstraZeneca and Daiichi Sankyo released positive data from the a trial of a treatment for breast cancer.
The phase-two trial studied the effects of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer who received two or more prior HER2-targeted regimens.
The primary endpoint of objective response rate confirmed by independent central review was 60.9% with trastuzumab deruxtecan monotherapy.
Patients achieved a disease control rate of 97.3% with a median duration of response of 14.8 months and median progression-free survival of 16.4 months.
The median overall survival had not yet been reached, with an estimated survival rate of 86% at one year.
The results were consistent across subgroups of patients.
'The clinically meaningful and durable responses seen among these patients illustrate the potential of trastuzumab deruxtecan to establish a new standard of care,' AstraZeneca executive vice-president of oncology R&D Jose Baselga said.
'These results are impressive, as women with this advanced stage of breast cancer have already endured multiple prior therapies for HER2-positive metastatic breast cancer.'
At 1:05pm: (LON:AZN) AstraZeneca PLC share price was +76p at 7322p